Karyopharm Therapeutics
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. Karyopharm Therapeutics's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 7% to $146,033,000. The net income raised on -$143,099,000 and profit margin reached -98%. Total operating expenses were $270,631,000.
Profit Margin
| 2014 | 229K | -75.77M | -33090.39% |
|---|---|---|---|
| 2015 | 250K | -118.18M | -47272.4% |
| 2016 | 154K | -109.57M | -71153.9% |
| 2017 | 1.60M | -128.98M | -8036.39% |
| 2018 | 30.33M | -178.40M | -588.1% |
| 2019 | 40.89M | -199.59M | -488.08% |
| 2020 | 108.08M | -196.27M | -181.59% |
| 2021 | 209.81M | -124.08M | -59.14% |
| 2022 | 157.07M | -165.29M | -105.23% |
| 2023 | 146.03M | -143.09M | -97.99% |
KPTI Income Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||
Revenue | 146.03M | 157.07M | 209.81M | 108.08M | 40.89M | 30.33M | 1.60M | 154K | 250K | 229K |
Cost of revenue | 4.94M | 5.21M | 3.40M | 2.70M | 2.40M | 0 | 107.27M | 0 | 97.74M | 60.12M |
Gross profit | 141.09M | 151.86M | 206.41M | 105.38M | 38.48M | 30.33M | -105.66M | 154K | -97.49M | -59.89M |
Operating exp. | ||||||||||
Research and development | 138.75M | 148.66M | 160.84M | 150.81M | 122.34M | 161.37M | 107.27M | 86.93M | 97.74M | 60.12M |
Selling and marketing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total operating expenses | 270.63M | 294.06M | 304.68M | 277.23M | 227.76M | 210.21M | 132.14M | 110.88M | 119.32M | 76.07M |
Operating income | -129.53M | -142.20M | -98.27M | -171.85M | -189.27M | -179.88M | -130.53M | -110.73M | -119.07M | -75.84M |
Other income (expenses), net | -13.23M | -22.72M | -25.54M | -24.11M | -10.27M | 1.50M | 1.61M | 10K | 895K | 69K |
Income before tax | -142.77M | -164.92M | -123.82M | -195.96M | -199.55M | -178.38M | -128.92M | -109.43M | -118.18M | -75.77M |
Income tax expense | 323K | 369K | 268K | 309K | 40K | 26K | 63K | 139K | -895K | -69K |
Net income | -143.09M | -165.29M | -124.08M | -196.27M | -199.59M | -178.40M | -128.98M | -109.57M | -118.18M | -75.77M |
Earnings per share | ||||||||||
Basic EPS | -1.25 | -2.02 | -1.65 | -2.72 | -3.22 | -3.14 | -2.81 | -2.92 | -3.32 | -2.43 |
Diluted EPS | -1.25 | -2.02 | -1.65 | -2.72 | -3.22 | -3.14 | -2.81 | -2.92 | -3.32 | -2.43 |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |